Filtered By:
Specialty: Neurology
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 360 results found since Jan 2013.

Poststroke epilepsy: update and future directions
Stroke is among the most common causes of epilepsy after middle age. Patients with poststroke epilepsy (PSE) differ in several respects from patients with other forms of structural–metabolic epilepsy; not least in age, age-related sensitivity to side effects of antiepileptic drugs (AEDs), and specific drug–drug interaction issues related to secondary-stroke prophylaxis. Encouragingly, there has lately been remarkable activity in the study of PSE. Three developments in PSE research deserve particular focus. First, large prospective trials have established the incidence and risk factors of PSE in the setting of m...
Source: Therapeutic Advances in Neurological Disorders - August 14, 2016 Category: Neurology Authors: Zelano, J. Tags: Reviews Source Type: research

Risk Profile of Symptomatic Lacunar Stroke Versus Nonlobar Intracerebral Hemorrhage Brief Reports
Conclusions— The risk factor profile of dICH differs from that associated with LS. This might be used for disease risk stratification at individual level.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Morotti, A., Paciaroni, M., Zini, A., Silvestrelli, G., Del Zotto, E., Caso, V., DellAcqua, M. L., Simone, A. M., Lanari, A., Costa, P., Poli, L., De Giuli, V., Gamba, M., Ciccone, A., Ritelli, M., Di Castelnuovo, A., Iacoviello, L., Colombi, M., Agnelli, Tags: Intracranial Hemorrhage, Ischemic Stroke Brief Reports Source Type: research

A Young Woman with Ischemic Stroke: Should We Pay More Attention to Varicella Zoster Infection?
In conclusion, VZV vasculopathy needs to be considered in young adults with stroke. A high index of suspicion and early treatment seem to be important to minimize morbidity and mortality. Anticoagulation should probably be avoided in stroke associated with VZV vasculopathy.Case Rep Neurol 2016;8:145–150
Source: Case Reports in Neurology - July 7, 2016 Category: Neurology Source Type: research

Influence of Statin Pretreatment on Initial Neurological Severity and Short-Term Functional Outcome in Acute Ischemic Stroke Patients: The Fukuoka Stroke Registry
This study aimed at determining these associations in ischemic stroke patients. Methods: Among patients registered in the Fukuoka Stroke Registry from June 2007 to October 2014, 3,848 patients with ischemic stroke within 24 h of onset, who had been functionally independent before onset, were enrolled in this study. Ischemic stroke was classified as cardioembolic or non-cardioembolic infarction. Primary and secondary study outcomes were mild neurological symptoms defined as a National Institutes of Health Stroke Scale score of ≤4 on admission and favorable functional outcome defined as a modified Rankin Scale score of ≤...
Source: Cerebrovascular Diseases - July 4, 2016 Category: Neurology Source Type: research

Previous Statin Use and High-Resolution Magnetic Resonance Imaging Characteristics of Intracranial Atherosclerotic Plaque: The Intensive Statin Treatment in Acute Ischemic Stroke Patients With Intracranial Atherosclerosis Study Clinical Sciences
Conclusions— Premorbid statin usage is independently associated with reduced plaque enhancement and a decrease in large cortical lesions in patients with intracranial atherosclerotic stroke.
Source: Stroke - June 26, 2016 Category: Neurology Authors: Chung, J.-W., Hwang, J., Lee, M. J., Cha, J., Bang, O. Y. Tags: Lipids and Cholesterol, Magnetic Resonance Imaging (MRI), Treatment, Cerebrovascular Disease/Stroke, Ischemic Stroke Clinical Sciences Source Type: research

Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage
Opinion statement New neuroprotective treatments aimed at preventing or minimizing “delayed brain injury” are attractive areas of investigation and hold the potential to have substantial beneficial effects on aneurysmal subarachnoid hemorrhage (aSAH) survivors. The underlying mechanisms for this “delayed brain injury” are multi-factorial and not fully understood. The most ideal treatment strategies would have the potential for a pleotropic effect positively modulating multiple implicated pathophysiological mechanisms at once. My personal management (RFJ) of patients with aneurysmal subarachnoid hemorrhage...
Source: Current Treatment Options in Neurology - June 19, 2016 Category: Neurology Source Type: research

Statin Medication Use and Nosocomial Infection Risk in the Acute Phase of Stroke
Statins have immunomodulatory and peripheral anti-inflammatory properties that are independent of their lipid-lowering action. Whether these properties reduce the risk for developing poststroke infection is debated in clinical literature. We estimated the risk for developing nosocomial poststroke infection based on statin exposure in patients aged 18 or older hospitalized for ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - June 8, 2016 Category: Neurology Authors: Douglas L. Weeks, Christopher L. Greer, Megan N. Willson Source Type: research

Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage
Conclusions: Longitudinal lipid levels differ between ICH cases and non-ICH controls, most notably for a decline in serum TC and LDL levels within 6 months preceding primary ICH, independent of statin or alcohol use. These changes in serum TC and LDL trends suggest a biological pathway that precipitates ICH occurrence. Further studies are needed to replicate these results and characterize rate of change in serum lipids as a potential biomarker of impending acute cerebral injury.
Source: Neurology - May 29, 2016 Category: Neurology Authors: Phuah, C.-L., Raffeld, M. R., Ayres, A. M., Viswanathan, A., Greenberg, S. M., Biffi, A., Rosand, J., Anderson, C. D. Tags: All Cerebrovascular disease/Stroke, Intracerebral hemorrhage ARTICLE Source Type: research

Progressive Cortical Neuronal Damage and Chronic Hemodynamic Impairment in Atherosclerotic Major Cerebral Artery Disease Clinical Sciences
Conclusions— In patients with atherosclerotic internal carotid artery or middle cerebral artery disease, the progression of cortical neuronal damage was associated with hemodynamic impairment at baseline and hemodynamic deterioration during follow-up. Statin use may be beneficial against hemodynamic deterioration and therefore neuroprotective.
Source: Stroke - May 22, 2016 Category: Neurology Authors: Yamauchi, H., Kagawa, S., Kishibe, Y., Takahashi, M., Higashi, T. Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Clinical Sciences Source Type: research

Statin use after intracerebral hemorrhage: a 10 ‐year nationwide cohort study
ConclusionHydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on recurrent ICH or other components of the composite outcome. Additional studies are required to clarify the biological mechanisms underlying these observations. Statin therapy has demonstrated benefits in ischemic stroke patients, but statin use and intracerebral hemorrhage (ICH) remain a concern. Hydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on rec...
Source: Brain and Behavior - May 12, 2016 Category: Neurology Authors: Shu ‐Yu Tai, Feng‐Cheng Lin, Chung‐Yin Lee, Chai‐Jan Chang, Ming‐Tsang Wu, Chen‐Yu Chien Tags: Original Research Source Type: research

Statins and risk of poststroke hemorrhagic complications
Conclusions: Statin use prior to AIS was not associated with early hemorrhagic complications, irrespective of treatment with thrombolysis. New initiation of statin treatment early after AIS did not affect risk of postacute ICH, but might be associated with reduced mortality.
Source: Neurology - April 24, 2016 Category: Neurology Authors: Scheitz, J. F., MacIsaac, R. L., Abdul-Rahim, A. H., Siegerink, B., Bath, P. M., Endres, M., Lees, K. R., Nolte, C. H., On behalf of the VISTA collaboration Tags: Infarction, Intracerebral hemorrhage ARTICLE Source Type: research

Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance
Post hoc analyses of data from randomized controlled trials can generate useful hypotheses, but need to be considered exploratory. When conducted, such evaluations should adhere to specified criteria and test for a treatment by subgroup interaction for the trial's primary endpoint.1 The best way to proceed if unexpected but potentially important outcomes occur is less clear. Concern that treatment with HMG-CoA reductase inhibitors (i.e., statins) might increase the risk of poststroke intracerebral hemorrhage (ICH) arose from an unanticipated observation in the Stroke Prevention with Aggressive Reduction in Cholesterol Leve...
Source: Neurology - April 24, 2016 Category: Neurology Authors: Goldstein, L. B., Nederkoorn, P. J. Tags: All Cerebrovascular disease/Stroke, Intracerebral hemorrhage EDITORIALS Source Type: research

The contemporary management of intracranial atherosclerotic disease.
Authors: Leng X, Wong KS, Leung TW Abstract Intracranial atherosclerotic disease is the most common cause of cerebral vasculopathy and an important stroke etiology worldwide, with a higher prevalence in Asian, Hispanic and African ethnicities. Symptomatic intracranial atherosclerotic disease portends a recurrent stroke risk as high as 18% at one year. The key to secondary prevention is an understanding of the underlying stroke mechanism and aggressive control of conventional cardiovascular risks. Contemporary treatment includes antiplatelet therapy, optimal glycemic and blood pressure control, statin therapy and li...
Source: Expert Review of Neurotherapeutics - April 18, 2016 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Aggressive Medical Management for ICAD: A Comparison to the SAMMPRIS Trial (P1.174)
Conclusions:In a single center observational cohort study, we found that AMM in symptomatic ICAD yielded higher rates of recurrent stroke at 30 days when compared to the SAMMPRIS trial. This indicates that it may be more difficult to replicate the AMM and lifestyle modifications that were implemented in the SAMMPRIS trial and warrants further investigation.Disclosure: Dr. Sangha has nothing to disclose. Dr. Ansari has nothing to disclose. Dr. Bernstein has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., and Pfizer Inc. as a speaker/advisory board member. Dr. Corado has nothing...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Sangha, R., Ansari, S., Bernstein, R., Corado, C., Curran, Y., Ruff, I., Prabhakaran, S. Tags: Cerebrovascular Disease: Risk Factors and Prevention Source Type: research